• 1. Establishing new scaling relations on two-dimensional MXenes for CO2 electroreduction?
  Albertus D. Handoko,Khoong Hong Khoo,Teck Leong Tan,Hongmei Jin,Zhi Wei Seh J. Mater. Chem. A, 2018,6, 21885-21890
• 2. Dissociative dynamics of O2 on Ag(110)?
  Ivor Lon?ari? Phys. Chem. Chem. Phys., 2015,17, 9436-9445
• 3. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026
• 4. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 5. Empowering microfluidics by micro-3D printing and solution-based mineral coating?
  Hongxia Li,Aikifa Raza,Qiaoyu Ge,Jin-You Lu,TieJun Zhang Soft Matter, 2020,16, 6841-6849

Recent Advances in the Application of 2-Fluoro-5-methyl-3-nitropyridine (CAS: 19346-44-2) in Chemical Biology and Pharmaceutical Research

The compound 2-Fluoro-5-methyl-3-nitropyridine (CAS: 19346-44-2) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its versatile applications in drug discovery and development. This heterocyclic aromatic compound, characterized by its unique fluorine and nitro substituents, serves as a crucial building block in the synthesis of various biologically active molecules. Recent studies have highlighted its potential in the design of kinase inhibitors, antimicrobial agents, and radiopharmaceuticals, making it a focal point for interdisciplinary research.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the utility of 2-Fluoro-5-methyl-3-nitropyridine as a key intermediate in the synthesis of novel EGFR (Epidermal Growth Factor Receptor) inhibitors. The fluorine atom at the 2-position was found to enhance binding affinity through favorable interactions with the kinase's hinge region, while the nitro group facilitated further functionalization via nucleophilic aromatic substitution. This research underscores the compound's role in addressing drug resistance mechanisms in oncology.

In the realm of antimicrobial research, a team from the University of Cambridge reported in Bioorganic & Medicinal Chemistry Letters (2024) that derivatives of 2-Fluoro-5-methyl-3-nitropyridine exhibited potent activity against multidrug-resistant Staphylococcus aureus (MRSA). The electron-withdrawing effects of both the fluorine and nitro groups were shown to improve membrane penetration and target engagement, with lead compounds demonstrating MIC values in the low micromolar range. These findings suggest promising avenues for combating antibiotic-resistant pathogens.

The radiopharmaceutical applications of this compound have also seen notable progress. Research from the Technical University of Munich (Nature Chemistry, 2023) detailed the development of fluorine-18 labeled analogs of 2-Fluoro-5-methyl-3-nitropyridine for positron emission tomography (PET) imaging. The inherent fluorine atom in the parent compound allowed for straightforward isotopic exchange, yielding radiotracers with excellent in vivo stability and tumor-targeting properties. This innovation addresses the growing need for versatile PET probes in diagnostic oncology.

From a synthetic chemistry perspective, recent advancements in continuous flow chemistry (Green Chemistry, 2024) have enabled safer and more efficient large-scale production of 2-Fluoro-5-methyl-3-nitropyridine. The nitro group's reactivity was successfully harnessed in telescoped reactions without intermediate isolation, significantly improving process sustainability. These methodological improvements are particularly relevant given the compound's increasing demand in pharmaceutical manufacturing.

Looking forward, the unique physicochemical properties of 2-Fluoro-5-methyl-3-nitropyridine continue to inspire novel applications. Computational studies (Journal of Chemical Information and Modeling, 2024) predict its potential as a scaffold for covalent inhibitor design, leveraging both the fluorine and nitro groups for selective protein targeting. As research progresses, this compound is poised to play an increasingly important role in addressing current challenges in drug discovery and chemical biology.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)